ProfessorAdele Holloway

Dean Learning and Teaching Performance, Health

Office of Health

  • Dean Learning and Teaching Performance, Health
    Office of Health
  • +61 3 6226 2670 (Work)
  • Tasmanian School of Medicine, Medicine, 337a Medical Science 2 (MS2), Hobart CBD Campuses, TAS

FUNDED PROJECTS

  • GRANT
    Applying innovative 'omics' technologies to identify key molecular drivers of metastatic bone tumours
    1 Jul 2021 - 30 Jun 2022
    People funded by this grant:
    • Raspin K,
    • Dickinson J,
    • FitzGerald L,
    • Holloway A
    Project Total: $14,778; Once cancers have spread, they become difficult to treat and increasingly resistant to therapy. Consequently, survival rates plummet, particularly for those with bone metastases. Using cutting-edge technologies, we have identified key changes in genes that allow metastatic tumour cells to survive in bone. We aim to characterise the metastatic capabilities of these key changes and determine their value as prognostic/therapeutic targets. Funded by: Cancer Council of Tasmania - Grant-Small ($14,778); University of Tasmania.
  • GRANT
    Examining DNA hydroxymethylation as a radiosensitisation target in medulloblastoma
    1 Jul 2021 - 30 Jun 2022
    People funded by this grant:
    • Brettingham-Moore K,
    • Taberlay P,
    • Holloway A
    Project Total: $11,000; Radiotherapy is frequently used in treating brain cancers such as medulloblastoma. Unfortunately, outcomes are poor for many patients. This study will investigate the potential of targeting DNA hydroxymethylation to sensitise medulloblastoma cells to radiotherapy. Aim 1 will profile levels of hydroxymethylation while Aim 2 will assess the impact of TET inhibition on response to radiotherapy. Funded by: Cancer Council of Tasmania - Grant-Small ($11,000); University of Tasmania.
  • GRANT
    Gaining new insights into metastatic bone tumours
    1 Jan 2020 - 30 Jun 2021
    People funded by this grant:
    • Dickinson J,
    • Holloway A,
    • Nott L,
    • Liu G-S,
    • FitzGerald L
    Project Total: $24,925; Molecular analysis of prostate cancer tumour specimen to identify new molecular targets for therapy. Funded by: Royal Hobart Hospital Research Foundation - Grant-Project ($24,925); University of Tasmania.
  • GRANT
    The impact of repeated DNA damage on the molecular profile of prostate cancer cells
    1 Jan 2019 - 28 Feb 2020
    People funded by this grant:
    • Brettingham-Moore K,
    • Black A,
    • Taberlay P,
    • Holloway A
    Project Total: $23,295; Many cancer patients receive fractionated/recurrent dosages of DNA damaging agents and there is some evidence that this may drive future treatment resistance and metastasis. This project will profile prostate cancer cells after repeated DNA damage via RNA-seq and EPIC arrays Funded by: Royal Hobart Hospital Research Foundation - Grant-Project ($23,295); University of Tasmania.
  • GRANT
    A Clinical and Biospecimens Prostate Cancer Resource for Biomarker Research in Tasmania
    1 Jan 2018 - 31 Aug 2019
    People funded by this grant:
    • FitzGerald L,
    • Dickinson J,
    • Skala M,
    • Stokes B,
    • Donovan S
    Project Total: $22,146; We propose to build upon the clinically-focused Prostate Cancer Outcomes Registry, Tasmania (PCOR-TAS) and collect matched biological samples to create a valuable resource for both clinicians and scientists. The availability of clinical and genetic data will allow important biomarker research into predicting prostate cancer outcomes and improving treatment strategies. Funded by: Royal Hobart Hospital Research Foundation - Grant-Minor Project ($22,146); University of Tasmania ($62,460).
  • GRANT
    Developing CRISPR/Cas Library Screens for identifying Novel Cancer Therapies
    1 Nov 2017 - 31 Oct 2018
    People funded by this grant:
    • Taberlay P,
    • Hewitt A,
    • Holloway A,
    • Liu G-S,
    • Dickinson J
    Project Total: $63,845; Our understanding of many cancers has improved dramatically over the past decade predominantly due to our ability to sequence entire genomes, at scale. Yet, we still require a better understanding of the underlying mechanisms that initiate and perpetuate cancers, as well as gene-based factors that initiate the transition from indolent to aggressive cancers with a propensity to metastasize. CRISPR/Cas is proving a robust, powerful and necessary tool in the laboratory that will undoubtedly underpin the next breakthrough in the field of cancer. As such, it is essential that we develop this capability at the University of Tasmania in a timely manner. The specific AIMS of this proposal are to: Aim 1: Establish CRISPR/Cas screening at the University of Tasmania as a tool to identify genes that drive aggressive and metastatic cancers. Aim 2: Perform a genome-wide CRISPR/Cas negative selection (loss-of-function) screen to identify genes essential for proliferation and survival, as well as metastatic behaviour. Funded by: University of Tasmania Foundation Inc - Grant-Cancer Research; University of Tasmania ($63,845).
  • CONSULTANCY/CONTRACT RESEARCH
    Identifying the Underlying Genetic Drivers of IPF using Complementary Approaches
    1 Jan 2017 - 31 Dec 2024
    People funded by this grant:
    • Dickinson J,
    • Corte T,
    • Holloway A,
    • Charlesworth J,
    • Walters H
    Project Total: $1,481,558; In the first instance the goal is to define the contribution of genetic variants to IPF in the Australian population, and we are in a unique position in Australia through our collaboration with Professor Schwartz. Our focus in this particular project is on rare genetic variation, and whilst it is likely that common variation will be similar to other mostly Caucasian populations there are likely to be differences in the rare variants in genes contributing to disease in the different populations. It is therefore important that these types of studies are performed in our population if we are going to understand the biology of disease in our patients. As discussed the identification of rare variants underpinning complex disease is proving fruitful both in understanding the biology of disease, the spectrum of clinical manifestations observed and importantly providing new potential targets for therapy. Funded by: Lung Foundation Australia ($1,481,558); University of Tasmania.
  • GRANT
    Mapping epigenomic information in a three-dimensional prostate cancer cell environment
    1 Jan 2017 - 30 Mar 2019
    People funded by this grant:
    • Taberlay P,
    • Brettingham-Moore K,
    • Holloway A,
    • Biro M
    Project Total: $20,990; We lack a model that better replicates in vivo tumour development to study epigenomic mechanisms of prostate cancer. To date, epigenetic changes in cancer have been investigated in homogenous cell lines from two-dimensional laboratory cultures or end-point tumour samples (static) from patients. Without doubt these studies have provided great insight into epigenetic differences that distinguish cancer cells from normal cells. However, there is a glaring lack of information about dynamic and temporal changes to the epigenome and cell behaviour as the cells acquire invasive potential. This is not possible using currently available two-dimensional models and clinical samples. We will address this deficit by establishing a three-dimensional model of prostate cancer that allows us to map how epigenomes and cell behaviours change during cancer development. Funded by: Cancer Council of Tasmania - Grant-Cancer Research ($20,990); University of Tasmania.
  • GRANT
    Molecular profiling of the post radiotherapy chromatin landscape in prostate cancer cells
    31 Jan 2016 - 30 Jun 2017
    People funded by this grant:
    • Brettingham-Moore K,
    • Ambrose M,
    • Holloway A,
    • Skala M,
    • Taberlay P
    Project Total: $33,000; This project will investigate the basal and post radiotherapy epigenetic changes in prostate cancer cells with divergent response to radiotherapy (RT). It will validate methylation data obtained from illumina Infinium 450 beadchip arrays, profile histone modifications post RT and investigate DNA damage post RT in cells treated with inhibitors of epigenetic enzymes (DNMT and HDAC). Funded by: Cancer Council of Tasmania - Grant-Cancer Research ($33,000); University of Tasmania.
  • GRANT
    David Collins Leukaemia Foundation Elite Research Scholarship - Epigenetic and Transcriptional regulation of leukaemia
    1 Jan 2016 - 31 Dec 2019
    People funded by this grant:
    • Holloway A,
    • Dickinson J,
    • Brettingham-Moore K
    Project Total: $153,000; This project will investigate how epigenetic and transcription factors co-operate to control gene expression, how this is reprogrammed in leukaemia and how epigenetic drugs impact these gene expression programs. Funded by: David Collins Leukaemia Foundation - Donation ($153,000); University of Tasmania.
  • GRANT
    Exploring the mechanisms responsible for the early transformation from chronic colitis to colorectal cancer
    1 Jan 2016 - 31 Dec 2016
    People funded by this grant:
    • Kunde D,
    • Eri R,
    • Holloway A
    Project Total: $28,000; This project will be the first study to model early changes in inflammation-associated colitis without the need for carcinogen treatment, which mirrors the clinical situation of human colitis. The project will study the histological and biochemical changes associated with the development of colorectal cancer in this mouse model that closely resembles the development seen in humans. The project will also investigate the mirobiome changes in the progression. Funded by: Cancer Council of Tasmania - Grant-Cancer Research ($28,000); University of Tasmania.
  • GRANT
    Embedding the benefits of undergraduate research experiences for medical research and health professional students
    15 Oct 2015 - 31 Jan 2017
    People funded by this grant:
    • Holloway A,
    • Williams A-M,
    • Radford J,
    • Ogden K,
    • Clegg L
    Project Total: $30,000; The purpose of the project is to improve expectations and outcomes of research experiences in undergraduate medical research and health professional students. The project team will analyse the student responses, comparing these to existing TREASURE data and evaluating student perceptions and learning1, 2. Our improved understanding of how students perceive research in the context of the health professions will be used to develop scaffolded approaches to undergraduate research, to better inform student expectations and better prepare students for undergraduate research experiences. Funded by: Office for Learning & Teaching - Grant-Extension Funding ($30,000); University of Tasmania.
  • GRANT
    Bi-functional opioids as a novel cancer treatment
    1 Feb 2015 - 30 Mar 2016
    People funded by this grant:
    • Dietis N,
    • Liu J,
    • Holloway A,
    • Guven N
    Project Total: $6,567; The aim of our study is to assess the anticancer effect of our 10 novel opioid drugs in six different intestinal cancer cell lines and compare them with oxaliplatin and irinotecan. The particular objectives of the study are: 1. To evaluate the effect of our novel drugs on intestinal cancer cell viability, growth, proliferation and ability to form colonies. 2. To explore the molecular mechanisms of the anticancer activity of our novel drugs. Funded by: Cancer Council of Tasmania - Grant-Cancer Research ($6,567); University of Tasmania.
  • GRANT
    Epigenetic regulation of inegrin beta 4 as a predictor of prostate cancer progression
    1 Feb 2015 - 31 Mar 2016
    People funded by this grant:
    • Holloway A,
    • Dickinson J,
    • Brettingham-Moore K,
    • Rao S,
    • Black A
    Project Total: $14,750; Prostate cancer diagnoses continue to rise rapidly in Australia, but of most concern is our current inability to distinguish aggressive tumours with propensity to metastasize from more indolent disease. This results in unnecessary treatment of many men whose cancer may never progress to clinically significant disease. However, progression of the disease results in aggressive, metastatic tumours which are difficult to treat and are associated with poor prognosis. We thus urgently require a better understanding of the underlying drivers of this disease, and particularly the factors and mechanisms that drive the transition to more aggressive tumours with a propensity to spread. These factors may represent biomarkers and potential therapeutic targets in prostate cancer progression. The aims of this study are therefore: 1.To determine whether epigenetic changes at the ITGB4 gene are associated with its increased expression in prostate cancer progression, and 2. To investigate whether epigenetic changes at the ITGB4 gene in prostate cancer are driven by the RUNX transcription factors. Funded by: Cancer Council of Tasmania - Grant-Cancer Research ($14,750); University of Tasmania.
  • GRANT
    Intersection of RUNX and integrin families in leukaemia
    1 Apr 2014 - 30 Jun 2015
    People funded by this grant:
    • Holloway A,
    • Dickinson J
    Project Total: $30,000; Funded by: David Collins Leukaemia Foundation - Grant ($30,000); University of Tasmania.
  • GRANT
    Familial Haematological Malignancies: understanding the role of inherited causative factors
    1 Mar 2014 - 30 Jun 2015
    People funded by this grant:
    • Dickinson J,
    • Charlesworth J,
    • Foote S,
    • Thomson R,
    • Holloway A
    Project Total: $20,000; Genetic factors are known to contribute to the risk of developing haematological malignancies, however to date the underlying genetic drivers of disease development remain largely unknown. Knowing the causative genes is not only important in understanding the disease process but also provides a range of benefits in the diagnosis, development of tailored treatments, and identification of new targets for therapy. Studying families with multiple cases of these diseases is a powerful approach used to identify the causative genes. Funded by: Cancer Council of Tasmania - Grant-Cancer Research ($20,000); University of Tasmania.
  • GRANT
    Combining deep sequencing and linkage approaches to identify rare variants contributing to familial prostate cancers
    1 Nov 2013 - 31 Dec 2014
    People funded by this grant:
    • Dickinson J,
    • Thomson R,
    • Charlesworth J,
    • Holloway A,
    • Jarman S
    Project Total: $35,000; Funded by: Cancer Council of Tasmania - Grant-Cancer Research ($35,000); University of Tasmania.
  • GRANT
    Regulation of Integrin Gene Expression Programs by RUNX in Cancer
    7 Mar 2013 - 7 Mar 2017
    People funded by this grant:
    • Holloway A,
    • Dickinson J
    Project Total: $26,250; The incidence of leukaemia continues to increase in Tasmania despite advances in our understanding and treatment of the disease. A gene which is often disrupted in leukaemia is a master regulator called RUNX1, which controls how and when other genes are switched on in blood cells. This project hypothesises that RUNX1 controls cell surface molecules called integrins. It proposes that disruption of RUNX1 in blood cells leads to the development of leukaemia by altering the integrins on the surface of the cells. Funded by: Cancer Council of Tasmania - Scholarship-PhD Top-Up Grant ($26,250); University of Tasmania.
  • GRANT
    Regulation of integrins by RUNX1 in leukaemia
    1 Jan 2013 - 30 Jun 2014
    People funded by this grant:
    • Holloway A,
    • Dickinson J,
    • Brettingham-Moore K
    Project Total: $30,000; Funded by: David Collins Leukaemia Foundation - Grant ($30,000); University of Tasmania.
  • GRANT
    The role of epigenetic changes in the progression of clinical disease in Multiple Endocrine Neoplasia Type 1 (MEN 1)
    1 Jan 2013 - 31 Dec 2013
    People funded by this grant:
    • Burgess J,
    • Prentice L,
    • Holloway A,
    • Dickinson J
    Project Total: $22,500; Funded by: Royal Hobart Hospital Research Foundation - Grant-Research ($22,500); University of Tasmania.
  • GRANT
    Epigenetic regulation of T-cell gene expression programs
    1 Sep 2012 - 31 Aug 2013
    People funded by this grant:
    • Holloway A,
    • Korner H
    Project Total: $8,505; Funded by: The Select Foundation - Grant-Small Grants Scheme ($8,505); University of Tasmania.
  • GRANT
    Epigenetic Regulation of Tumour Supressors in Skin Cancer
    7 May 2012 - 27 Oct 2013
    People funded by this grant:
    • Cook T,
    • Snow E,
    • Holloway A
    Project Total: $22,300; Funded by: Cancer Council of Tasmania - Grant-Small ($22,300); University of Tasmania.
  • GRANT
    Prostate cancer risk variants in integrin genes & their role in prostate cancer development
    1 Jan 2012 - 31 Oct 2013
    People funded by this grant:
    • Dickinson J,
    • Holloway A,
    • McMorran B,
    • Thomson R
    Project Total: $49,362; Funded by: Cancer Council of Tasmania - Grant-Cancer Research ($49,362); University of Tasmania.
  • GRANT
    Regulation of gene expression in cancer
    1 Jan 2012 - 30 Jun 2014
    People funded by this grant:
    • Holloway A
    Project Total: $4,500; Funded by: Donation via University of Tasmania Foundation - Donation ($4,500); University of Tasmania.
  • GRANT
    Epigenomics of familial prostate cancer
    1 Jul 2011 - 31 Mar 2013
    People funded by this grant:
    • Charlesworth J,
    • Holloway A,
    • Dickinson J
    Project Total: $14,000; Funded by: Cancer Council of Tasmania - Grant-Small ($14,000); University of Tasmania.